RCP unveils new UK base and EU plans

By Gareth Macdonald

- Last updated on GMT

Related tags: United kingdom, European union, Europe

RCP Therapeutics, a developer of regenerative medicine, hopes that its new HQ in the UK will benefit from the country’s status as a financial centre and proximity to cost effective trial sites in Eastern Europe.

The new firm, which will focus on aggregating biopharmaceutical technologies and performing proof-of-concept work in developmental trials, recently acquired all intellectual property (IP) and assets from US-based biotechnology group Telemolecular.

Under that deal, RCP will retain Telemolecular’s research laboratory in Sacramento as its primary US R&D site. RCP also plans to increase the number of scientific staff at the Californian facility, which will also be developed as a US commercialisation base for its products.

Company CEO Robert Sexauer said that: “Our vision for the Company is focused on the convergence between nanotechnologies and cellular targeting in the area of regenerative medicine.​”

He added: “We are actively seeking to acquire IP rights to prime technology candidates in the field of regenerative medicine​,” adding that the company plans “to forge alliances with leading European research institutions to commercialise cell based technologies​.”

In relation to choosing London in the UK as its base, Sexauer said that the location provides “access to high quality research facilities with good potential for collaborative partnerships​.”

We believe that we can organise and conduct Phase I clinical studies faster and [with less expense] in the EU, especially in Eastern Europe. Indeed, clinical trials can be conducted under identical guidelines established by the FDA which has shown acceptance of data gathered in EU trials​,” added Sexauer.

He also suggested that RCP may set up additional European R&D facilities in the future and added that the “aggressive efforts​” and tax incentives being offered by European governments to assist the development of the emerging biotechnology sector would be a significant factor in any such decision.

Related topics: Markets & Regulations

Related news

Follow us


View more